Herbal formula NRICM102 tested as pneumonia Add-On treatment
NCT ID NCT07583992
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether NRICM102, a Traditional Chinese Medicine, can help adults with community-acquired pneumonia reach clinical stability faster when added to standard antibiotic therapy. About 150 hospitalized participants will take either NRICM102 or a placebo for 7 days, alongside usual care. Researchers will monitor symptoms, vital signs, and safety to see if the herbal treatment offers any added benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NRICM102 (a Traditional Chinese Medicine concentrated granule)
- What this could lead to
- If it works, this could provide an additional treatment option for community-acquired pneumonia, potentially speeding recovery and reducing hospital stays.
- What could go wrong
- This is a Phase 2 trial with only 150 participants, so results are preliminary. The herbal formula may not show significant benefit over placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBIOTIC THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Research Institute of Chinese Medicine, Ministry of Health and Welfare
Taipei, 11221, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibiotic lefamulin takes on Drug-Resistant pneumonia
- New care bundle slashes IV complications in kids at ER
- Could your Child's cough help diagnose asthma or pneumonia?
- One-Size-Fits-All lactate test may miss risks in ICU patients
- Pneumonia drug trial aims to protect arteries from hidden damage
- Could less be more? new trial tests lower antibiotic dose for pneumonia